LeonaBio Inc.
Last updated September 27, 2026
Organization details
- Legal name
- LeonaBio Inc.
- Former names
- Athira Pharma, Inc. M3 Biotechnology, Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Headquarters city
- Bothell
- Headquarters state / province
- Washington
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- LONA
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001620463
- EIN
- 45-3368487
Board of directors
-
Barbara Kosacz · DirectorSince 2023
-
Fred Callori · DirectorSince 2026
-
Grant Pickering · DirectorSince 2023
-
James A. Johnson · DirectorSince 2023
-
John M. Fluke Jr. · DirectorSince 2023
- Since 2023
-
Kelly A. Romano · DirectorSince 2023
-
Mark James Litton · Director · PRESIDENT and CEOSince 2023
-
Michael A. Panzara · DirectorSince 2023
-
Natalie C. Holles · DirectorSince 2026
-
Peter B. Silverman · DirectorSince 2026
Chief executives
Mark James Litton
· President and CEO
Dates unknown
Director election results
Annual meeting of June 22, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
88.2%
-
99.6%
-
99.7%
Board connections
5 of this board's directors also sit on 12 other boards.
- via Joseph Edelman
- via Natalie C. Holles
- via Kelly A. Romano
- via Joseph Edelman
- via Joseph Edelman
- via Joseph Edelman
- via Joseph Edelman
- via Joseph Edelman
- via Joseph Edelman
- via Kelly A. Romano
- via Grant Pickering
- via Peter B. Silverman
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $99,418
- 10 sales by 5 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 4, 2026 | Mark James Litton Director, Officer (PRESIDENT and CEO) | Open-market sale | −5,156 | $5.37 | $27,688 |
| Mar 4, 2026 | Renninger Robert Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | −906 | $5.37 | $4,865 |
| Mar 4, 2026 | Worthington Mark Officer (GENERAL COUNSEL and CCO) | Open-market sale | −1,328 | $5.37 | $7,131 |
| Mar 4, 2026 | CHURCH KEVIN Officer (CHIEF SCIENTIFIC OFFICER) | Open-market sale | −1,359 | $5.37 | $7,298 |
| Mar 4, 2026 | San Martin Javier Officer (CHIEF MEDICAL OFFICER) | Open-market sale | −1,720 | $5.37 | $9,236 |
| Mar 3, 2026 | Mark James Litton Director, Officer (PRESIDENT and CEO) | Option exercise | +22,254 | — | — |
| Mar 3, 2026 | Renninger Robert Officer (CHIEF FINANCIAL OFFICER) | Option exercise | +3,900 | — | — |
| Mar 3, 2026 | Worthington Mark Officer (GENERAL COUNSEL and CCO) | Option exercise | +5,726 | — | — |
| Mar 3, 2026 | CHURCH KEVIN Officer (CHIEF SCIENTIFIC OFFICER) | Option exercise | +5,856 | — | — |
| Mar 3, 2026 | San Martin Javier Officer (CHIEF MEDICAL OFFICER) | Option exercise | +7,418 | — | — |
| Jan 2, 2026 | San Martin Javier Officer (CHIEF MEDICAL OFFICER) | Open-market sale | −1,644 | $6.88 | $11,311 |
| Jan 2, 2026 | Mark James Litton Director, Officer (President and CEO) | Open-market sale | −2,586 | $6.88 | $17,792 |
| Jan 2, 2026 | Worthington Mark Officer (General Counsel and CCO) | Open-market sale | −876 | $6.88 | $6,027 |
| Jan 2, 2026 | Renninger Robert Officer (Chief Financial Officer) | Open-market sale | −297 | $6.88 | $2,043 |
| Jan 2, 2026 | CHURCH KEVIN Officer (CHIEF SCIENTIFIC OFFICER) | Open-market sale | −876 | $6.88 | $6,027 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.